Literature DB >> 9696844

Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions.

D M Koelle1, J M Frank, M L Johnson, W W Kwok.   

Abstract

The local cellular immune response to herpes simplex virus (HSV) is important in the control of recurrent HSV infection. The antiviral functions of infiltrating CD4-bearing T cells may include cytotoxicity, inhibition of viral growth, lymphokine secretion, and support of humoral and CD8 responses. The antigens recognized by many HSV-specific CD4 T cells localizing to genital HSV-2 lesions are unknown. T cells recognizing antigens encoded within map units 0. 67 to 0.73 of HSV DNA are frequently recovered from herpetic lesions. Expression cloning with this region of DNA now shows that tegument protein VP22 and the viral dUTPase, encoded by genes UL49 and UL50, respectively, are T-cell antigens. Separate epitopes in VP22 were defined for T-cell clones from each of three patients. Reactivity with the tegument protein encoded by UL21 was identified for an additional patient. Three new epitopes were identified in VP16, a tegument protein associated with VP22. Some tegument-specific CD4 T-cell clones exhibited cytotoxic activity against HSV-infected cells. These results suggest that herpes simplex tegument proteins are processed for antigen presentation in vivo and are possible candidate compounds for herpes simplex vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696844      PMCID: PMC109983     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes.

Authors:  D M Koelle; C M Posavad; G R Barnum; M L Johnson; J M Frank; L Corey
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

2.  Nomenclature for factors of the HLA system, 1996.

Authors:  J G Bodmer; S G Marsh; E D Albert; W F Bodmer; R E Bontrop; D Charron; B Dupont; H A Erlich; R Fauchet; B Mach; W R Mayr; P Parham; T Sasazuki; G M Schreuder; J L Strominger; A Svejgaard; P I Terasaki
Journal:  Tissue Antigens       Date:  1997-03

3.  Human herpes simplex virus (HSV)-specific CD8+ CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled.

Authors:  M A Tigges; S Leng; D C Johnson; R L Burke
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

4.  Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes.

Authors:  Z Mikloska; A L Cunningham
Journal:  J Gen Virol       Date:  1998-02       Impact factor: 3.891

5.  The genome sequence of herpes simplex virus type 2.

Authors:  A Dolan; F E Jamieson; C Cunningham; B C Barnett; D J McGeoch
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  T-cell epitope analysis using subtracted expression libraries (TEASEL): application to a 38-kDA autoantigen recognized by T cells from an insulin-dependent diabetic patient.

Authors:  P I Neophytou; B O Roep; S D Arden; E M Muir; G Duinkerken; A Kallan; R R de Vries; J C Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

7.  Preferential presentation of herpes simplex virus T-cell antigen by HLA DQA1*0501/DQB1*0201 in comparison to HLA DQA1*0201/DQB1*0201.

Authors:  D M Koelle; M L Johnson; A N Ekstrom; P Byers; W W Kwok
Journal:  Hum Immunol       Date:  1997-04-01       Impact factor: 2.850

8.  Variability of herpes simplex virus 1 gL and anti-gL antibodies that inhibit cell fusion but not viral infectivity.

Authors:  M J Novotny; M L Parish; P G Spear
Journal:  Virology       Date:  1996-07-01       Impact factor: 3.616

9.  Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis.

Authors:  K R Jerome; J F Tait; D M Koelle; L Corey
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

10.  HLA-DQB1 codon 57 is critical for peptide binding and recognition.

Authors:  W W Kwok; M E Domeier; M L Johnson; G T Nepom; D M Koelle
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  32 in total

Review 1.  Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.

Authors:  K J Laing; L Dong; J Sidney; A Sette; D M Koelle
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

2.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

3.  Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine.

Authors:  Lichen Jing; Jürgen Haas; Tiana M Chong; Joseph J Bruckner; Greg C Dann; Lichun Dong; Joshua O Marshak; Christopher L McClurkan; Tori N Yamamoto; Susanne M Bailer; Kerry J Laing; Anna Wald; Georges M G M Verjans; David M Koelle
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

4.  Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8+ TEM and TRM Cell Responses against Herpesvirus Infection and Disease.

Authors:  Patricia P Lopes; George Todorov; Thanh T Pham; Anthony B Nesburn; Elmostafa Bahraoui; Lbachir BenMohamed
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

5.  Homing in on the cellular immune response to HSV-2 in humans.

Authors:  David M Koelle; Julio C Gonzalez; Andrew S Johnson
Journal:  Am J Reprod Immunol       Date:  2005-04       Impact factor: 3.886

Review 6.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

7.  Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.

Authors:  Xiuli Zhang; Florence A Castelli; Xiaoming Zhu; Michele Wu; Bernard Maillère; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

8.  Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.

Authors:  Aziz Alami Chentoufi; Xavier Dervillez; Pierre-Alain Rubbo; Tiffany Kuo; Xiuli Zhang; Nicolas Nagot; Edouard Tuaillon; Philippe Van De Perre; Anthony B Nesburn; Lbachir Benmohamed
Journal:  Curr Trends Immunol       Date:  2012

9.  Intravaginal Zinc Oxide Tetrapod Nanoparticles as Novel Immunoprotective Agents against Genital Herpes.

Authors:  Thessicar E Antoine; Satvik R Hadigal; Abraam M Yakoub; Yogendra Kumar Mishra; Palash Bhattacharya; Christine Haddad; Tibor Valyi-Nagy; Rainer Adelung; Bellur S Prabhakar; Deepak Shukla
Journal:  J Immunol       Date:  2016-04-27       Impact factor: 5.422

10.  Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection.

Authors:  William J Muller; Lichun Dong; Adrian Vilalta; Benjamin Byrd; Kai M Wilhelm; Christopher L McClurkan; Michal Margalith; Chao Liu; David Kaslow; John Sidney; Alessandro Sette; David M Koelle
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.